Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

New study reports on the benefits of hyperthermia system to treat soft tissue sarcomas

BSD Medical : 15 September, 2008  (New Product)
A new article in Current Option in Oncology (Ref 1) has highlighted the use of BSD Medical’s BSD-2000 hyperthermia system in treating patients with high risk soft tissue sarcomas.
Central to the article’s review of sarcoma studies using the BSD-2000 is the results of a phase III study involving 341 randomized patients with high risk soft tissue sarcomas that showed an approximate doubling of disease-free survival time for patients who received treatments using BSD-2000 systems in combination with chemotherapy, surgery and radiation, as compared to those patients who received chemotherapy, surgery and radiation alone.

The additional use of hyperthermia delivered using the BSD-2000 made a difference in patient outcome. The study was conducted under the sponsorship and quality control of the European Organization for Research and Treatment of Cancer (EORTC:62961). Preliminary results of the study were reported at the American Society of Clinical Oncology (ASCO) 2007.

The article entitled “Regional hyperthermia in high-risk soft tissue sarcomas” was authored by Rolf D Issels, MD, PhD of the University Hospital Medical Center Grosshadern and Helmholtz Zentrum Munchen-German Research Center for Environmental Health, Munich, Germany. The author stated that, “The rationale for the combination of cytotoxic drugs with hyperthermia (increase of temperature in the range of 40 to 44 degrees C) is based on experimental and clinical evidence that heat increases killing of cells by direct thermal toxicity and shows thermal enhancement of drug efficacy.”

Ref 1- Current Option in Oncology 2008, 20:pages 438-443.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo